It depends on your state. Federal law lets state Medicaid programs exclude or restrict drugs used for weight loss [1]. Coverage can differ for the same drug depending on the diagnosis. Check the exact product, formulation and prescribed use with your Medicaid plan or state agency before filling it [7].
How to check your Medicaid coverage
Use the GLP-1 insurance worksheet to record the exact drug, formulation, prescribed indication, any approval requirements and your pharmacy’s network status. Ask the number on your Medicaid plan card for the current drug list and the written criteria. CMS lists state Medicaid contacts if you need help identifying which agency to call [7].
This page covers Medicaid only. Medicare runs on a different statutory rule, which is set out in whether Medicare covers Ozempic and Wegovy. Employer and marketplace plans follow their own terms, covered in what decides your bill.
Rule one: the exclusion is optional
The rule sits in section 1927 of the Social Security Act, in a list of drug uses a state may exclude from coverage or restrict. The first entry reads: “Agents when used for anorexia, weight loss, or weight gain” [1]. The operative word is may, which makes the exclusion a state choice. A state that uses the exclusion does not cover these drugs for weight. A state that does not use it is free to cover them.
That is why the answer changes at a state line. An analysis of 2023 pharmacy claims sorted each state’s Medicaid coverage into three groups: “not covered,” “restricted,” or “unrestricted” [2]. Use was nominally higher in the restricted and unrestricted states than in the not-covered ones [2]. The claims describe use in 2023. For current coverage, check the drug list and criteria for your Medicaid plan. CMS’s BALANCE model is voluntary for states, so its existence does not establish coverage in your program [6].
Rule two: the exclusion names a use, not a drug
The optional exclusion applies to the use for which a drug is prescribed [1]. A type 2 diabetes prescription falls outside the weight-loss exclusion, though the state or plan can still apply separate coverage and authorization criteria.
The same claims study measured diabetes use separately. In Medicaid, state use for diabetes tracked diabetes prevalence only weakly, while in commercial plans the link was strong [2]. Use for obesity showed weak or negligible links to obesity rates in every payer group [2]. In Medicaid, how common a condition was in a state said little about how often the drug was used there.
For semaglutide, our Wegovy and Ozempic comparison explains why the product and its approved uses matter. Brands used for weight management can also have other indications. Check which indication the prescriber documented.
Prior authorization and the MassHealth example
A state can require prior authorization for covered outpatient drugs [1]. The plan’s written criteria tell the prescriber what documentation to submit. A formulary listing by itself cannot tell you whether the request will be approved.
MassHealth ended routine coverage of medicines used for weight loss on July 3, 2026. Its notice describes continued consideration with prior authorization for other medically accepted uses, including specified cardiovascular, liver and sleep apnea indications. It also says requests for members under 21 are reviewed for medical necessity under EPSDT [5].
A study of the earlier MassHealth policy followed 7,493 adults who started Wegovy or Zepbound between July and December 2024 [3]. At six months, 60.8% met its refill definition of persistence, with no more than 56 days between fills. Using the study’s 80%-of-days-covered threshold, 60.1% met the definition of adherence [3].
What insurance data show about prescriptions and fills
One health system in Ohio and Florida studied records for 50,678 adults with obesity from 2015 to 2023. The cohort included adults who attended a weight-management program or received an initial prescription for an anti-obesity drug. Across the full cohort, 8.0% received a prescription for an anti-obesity drug and 4.4% filled one. Medicaid was associated with lower odds of both, compared with private insurance[4]. The study included older anti-obesity drugs and does not measure a specific state’s current GLP-1 coverage.
The analysis of semaglutide use by income and insurance examines a different population. Both studies describe associations with access.
If your plan denies the prescription
Ask the plan for the written reason, the applicable criteria and the deadline to challenge the decision. The prior authorization guide explains the documentation step. For a Medicaid managed-care denial, the written notice explains the plan appeal and the route to a state fair hearing [8].
If you are comparing self-pay options, the monthly GLP-1 cost guide shows how to separate medication from recurring fees and prepaid commitments. Compare the same product, formulation and supply period.